Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
12 p, 675.8 KB Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer : Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG / Hadji, Peyman (Krankenhaus Nordwest) ; Aapro, Matti S. (Genolier Cancer Center, Switzerland) ; Body, Jean-Jacques (CHU Brugmann, Université Libre de Bruxelles, Belgium) ; Gnant, Michael (Medical University of Vienna, Austria) ; Brandi, Maria Luisa (University of Florence, Italy) ; Reginster, Jean Yves (University of Liège, Belgium) ; Zillikens, M. Carola (Erasmus MC, Rotterdam, Netherlands) ; Glüer, Claus-C. (Univeristy of Kiel, Germany) ; de Villiers, Tobie (University of Stellenbosch, Cape Town, South Africa) ; Baber, Rod (University of Sydney, Australia) ; Roodman, G. David (Indiana University School of Medicine, USA) ; Cooper, Cyrus (University of Southampton, UK) ; Langdahl, Bente (Aarhus University, Denmark) ; Palacios, Santiago (Instituto Palacios Madrid, Spain) ; Kanis, John (Catholic University of Australia, Melbourne, Australia and University of Sheffield, UK) ; Al-Daghri, Nasser (University of Riyadh, Saudi Arabia) ; Nogués Solán, Xavier (Universitat Autònoma de Barcelona) ; Eriksen, Erik Fink (University of Oslo, Norway) ; Kurth, Andreas (Klinikum Birkenwerder, Germany) ; Rizzoli, Rene (Geneva University, Switzerland) ; Coleman, Robert E. (University of Sheffield, UK)
Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). [...]
2017 - 10.1016/j.jbo.2017.03.001
Journal of Bone Oncology, Vol. 7 (June 2017) , p. 1-12  
2.
11 p, 634.6 KB Diacerein : Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO / Pavelka, Karel (Institute of Rheumatology and Clinic of Rheumatology, Charles University) ; Bruyère, Olivier (Liège, Belgium) ; Cooper, Cyrus (Southampton, UK) ; Kanis, John A. (Sheffield, UK) ; Leeb, Burkhard F. (2nd Department of Medicine, State Hospital Stockerau, Centre for Rheumatology, Lower Austria, Karl Landsteiner Institute for Clinical Rheumatology, Stockerau, Austria) ; Maheu, Emmanuel (Rheumatology Department, AP-HP, St-Antoine Hospital) ; Martel-Pelletier, Johanne ; Monfort, Jordi (Hospital del Mar) ; Pelletier, Jean-Pierre (Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame-Hospital) ; Rizzoli, René (Division of Bone Diseases, Geneva University Hospital and Faculty of Medicine) ; Reginster, Jean-Yves (Department of Public Health, Epidemiology and Health Economics, University of Liège) ; Universitat Autònoma de Barcelona. Departament de Medicina
Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. [...]
2016 - 10.1007/s40266-016-0347-4
Drugs & Aging, Vol. 33 (february 2016) , p. 75-85  

Vegeu també: autors amb noms similars
5 Rizzoli, R.
4 Rizzoli, René
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.